X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (52) 52
male (40) 40
female (38) 38
middle aged (37) 37
aged (36) 36
adult (32) 32
hematology (32) 32
index medicus (21) 21
aged, 80 and over (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
oncology (11) 11
prognosis (11) 11
disease-free survival (10) 10
treatment outcome (10) 10
multiple myeloma (9) 9
adolescent (8) 8
leukemia (8) 8
multiple myeloma - drug therapy (8) 8
multiple myeloma - mortality (8) 8
survival (8) 8
survival rate (8) 8
follow-up studies (7) 7
transplantation (7) 7
chemotherapy (6) 6
prospective studies (6) 6
recurrence (6) 6
retrospective studies (6) 6
risk factors (6) 6
survival analysis (6) 6
thalidomide (6) 6
thalidomide - administration & dosage (6) 6
transplantation, autologous (6) 6
immunology (5) 5
lymphoma, non-hodgkin - drug therapy (5) 5
lymphoma, non-hodgkin - pathology (5) 5
multiple myeloma - pathology (5) 5
remission induction (5) 5
abridged index medicus (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
cancer (4) 4
care and treatment (4) 4
child (4) 4
chronic lymphocytic leukemia (4) 4
combined modality therapy (4) 4
cyclophosphamide (4) 4
dexamethasone - administration & dosage (4) 4
disease (4) 4
expression (4) 4
fludarabine (4) 4
italy - epidemiology (4) 4
leukemia, lymphocytic, chronic, b-cell - blood (4) 4
leukemia, lymphocytic, chronic, b-cell - genetics (4) 4
lymphoma, non-hodgkin - therapy (4) 4
mortality (4) 4
multiple myeloma - blood (4) 4
multiple myeloma - therapy (4) 4
neoplasm staging (4) 4
pegylated liposomal doxorubicin (4) 4
polymerase chain reaction (4) 4
soluble interleukin-2 receptor (4) 4
stem cells (4) 4
therapy (4) 4
time factors (4) 4
age factors (3) 3
b-cell lymphoma (3) 3
chromosome aberrations (3) 3
chronic lymphocytic-leukemia (3) 3
colony-stimulating factor (3) 3
complications and side effects (3) 3
dexamethasone (3) 3
diagnosis (3) 3
doxorubicin - administration & dosage (3) 3
doxorubicin - analogs & derivatives (3) 3
flow cytometry (3) 3
further section (3) 3
genetic aspects (3) 3
guidelines (3) 3
hematology, oncology and palliative medicine (3) 3
hematopoietic stem cell transplantation (3) 3
incidence (3) 3
interleukin-10 (3) 3
interleukin‐10 (3) 3
leukemia, lymphocytic, chronic, b-cell - enzymology (3) 3
leukemia, lymphocytic, chronic, b-cell - pathology (3) 3
lymphoma (3) 3
lymphoma, non-hodgkin - blood (3) 3
lymphoma, non-hodgkin - immunology (3) 3
melphalan - administration & dosage (3) 3
melphalan - therapeutic use (3) 3
microbiology (3) 3
mutation (3) 3
non-hodgkin's lymphoma (3) 3
non-hodgkins lymphoma (3) 3
non‐hodgkin's lymphoma (3) 3
original paper (3) 3
pathology (3) 3
prognostic-factors (3) 3
risk (3) 3
soluble interleukin‐2 receptor (3) 3
trial (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Girmenia, Corrado and Bertaina, Alice and Piciocchi, Alfonso and Perruccio, Katia and Algarotti, Alessandra and Busca, Alessandro and Cattaneo, Chiara and Raiola, Anna Maria and Guidi, Stefano and Iori, Anna Paola and Candoni, Anna and Irrera, Giuseppe and Milone, Giuseppe and Marcacci, Giampaolo and Scimè, Rosanna and Musso, Maurizio and Cudillo, Laura and Sica, Simona and Castagna, Luca and Corradini, Paolo and Marchesi, Francesco and Pastore, Domenico and Alessandrino, Emilio Paolo and Annaloro, Claudio and Ciceri, Fabio and Santarone, Stella and Nassi, Luca and Farina, Claudio and Viscoli, Claudio and Rossolini, Gian Maria and Bonifazi, Francesca and Rambaldi, Alessandro and Capria, Saveria and Bertaina, A and Mastronuzzi, Angela and Pagliara, Daria and Bernaschi, Paola and Amico, Lucia and Carotti, Alessandra and Mencacci, Antonella and Busca, A and Bruno, Benedetto and Costa, Cristina and Passi, Angela and Ravizzola, Giuseppe and Angelucci, Emanuele and Marchese, Anna and Pecile, Patrizia and Candoni, A and Ventura, Giovanna and Fanin, Renato and Scarparo, Claudio and Barbaro, Angelo and Leotta, Salvatore and Marchese, Anna Elisa and Marcacci, G and Becchimanzi, Cristina and Donnarumma, Daniela and Tringali, Stefania and Baldi, Maria Teresa and Scalone, Renato and Cudillo, L and Picardi, Alessandra and Arcese, William and Fontana, Carla and Sica, S and Giammarco, Sabrina and Spanu, Teresa and Castagna, L and Crocchiolo, Roberto and Casari, Erminia and Mussetti, Alberto and Conte, Eutilia and Ensoli, Fabrizio and Miragliotta, Giuseppe and Marone, Piero and Arghittu, Milena and Greco, Raffaella and Forcina, Alessandra and Chichero, Paola and Santarone, S and Di Bartolomeo, Paolo and Fazii, Paolo and Kroumova, Vesselina and Decembrino, Nunzia and Zecca, Marco and Pisapia, Giovanni and Palazzo, Giulia and Lanino, Edoardo and Faraci, Maura and Castagnola, Elio and Bandettini, Roberto and Pastano, Rocco and Sammassimo, Simona and Passerini, Rita and Stefani, Piero Maria and Gherlinzoni, Filippo and Rigoli, Roberto and Prezioso, Lucia and Cambò, Benedetta and ... and GITMO and AMCLI and Gruppo Italiano Trapianto di Midollo Osseo (GITMO) and Associazione Microbiologi Clinici Italiani (AMCLI)
Clinical Infectious Diseases, ISSN 1058-4838, 12/2017, Volume 65, Issue 11, pp. 1884 - 1896
Journal Article
American Journal of Hematology, ISSN 0361-8609, 06/2017, Volume 92, Issue 6, pp. 529 - 535
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1990 - 1990
Abstract INTRODUCTION: Twice weekly carfilzomib is approved at two different doses, 27 mg/m2 in combination with lenalidomide and dexamethasone, and 56 mg/m2... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 3240 - 3240
Abstract INTRODUCTION: High-risk cytogenetic abnormalities, such as del(17p), t(4;14), and/or t(14;16), are associated to an unfavorable prognosis. Several... 
Journal Article
Annals of Hematology, ISSN 0939-5555, 06/2010, Volume 89, Issue 6, pp. 591 - 596
Journal Article
Blood, ISSN 0006-4971, 09/2011, Volume 118, Issue 12, pp. 3419 - 3425
Journal Article
HAEMATOLOGICA, ISSN 0390-6078, 07/2019, Volume 104, Issue 8, pp. 1640 - 1647
Twice-weekly carfilzomib is approved at 27 and 56 mg/m(2) to treat relapsed multiple myeloma patients. In the phase III study ARROW, once-weekly 70 mg/m(2)... 
SURVIVAL | MULTICENTER | PHASE 1/2 | CYCLOPHOSPHAMIDE | LENALIDOMIDE | RISK | OPEN-LABEL | BORTEZOMIB | HEMATOLOGY | LOW-DOSE DEXAMETHASONE | Index Medicus
Journal Article
Therapeutic Advances in Medical Oncology, ISSN 1758-8340, 1/2017, Volume 9, Issue 1, pp. 22 - 32
Background: Many patients with solid tumours or nonmyeloid haematopoietic tumours develop symptomatic anaemia, which has a major impact on quality of life... 
epoetin alfa | erythropoiesis-stimulating agents | biosimilar | chemotherapy-induced anaemia | erythropoietin | HEMOGLOBIN | CHEMOTHERAPY-INDUCED ANEMIA | SAFETY | GUIDELINES | PATTERNS | CANCER-TREATMENT ACT | EUROPE | ONCOLOGY | OUTCOMES | Original Research
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 3235 - 3235
Abstract Introduction Multiple myeloma (MM) can be associated with paraskeletal (PP) or extramedullary (EMP) plasmocytomas (PL). Although PLs are relatively... 
Journal Article
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 3353 - 3353
Abstract Multiple Myeloma (MM) is a clonal B-cell disorder characterized by accumulation of malignant plasma cells (PCs) in the bone marrow (BM). Circulating... 
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 1828 - 1828
Abstract Background Carfilzomib is a novel second generation proteasome-inhibitor with significant anti-MM activity and favorable toxicity profile. In a recent... 
Journal Article